降糖药物与老年肌少症的研究进展  

The research progress on the antidiabetic agents related sarcopenia in elderly adults

作　　者：李丹茜 张晓琳[1] 周双[2] 刘新民[1] Li Danqian;Zhang Xiaolin;Zhou Shuang;Liu Xinmin(Department of Geriatrics,Peking University First Hospital,Beijing 100034,China;Department of Pharmacy,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院老年内科,北京100034 [2]北京大学第一医院药剂科,北京100034

出　　处：《中华老年医学杂志》2024年第12期1643-1650,共8页Chinese Journal of Geriatrics

基　　金：首都卫生发展科研专项(2022-3-70212);中央高水平医院临床科研业务费资助(北京大学第一医院)(2023IR37)。

摘　　要：肌少症是影响老年患者身体机能及生活质量的常见疾病之一。老年人群糖尿病患病率高,常存在多重用药,药物相关的肌肉损伤及肌少症发生风险大幅增加。因此,早期识别并替换高风险药物尤为重要。本文就可导致肌少症的降糖药物类型、作用机制、干预措施及药物管理进行综述,以促进老年人肌少症的防控、提高合理用药水平。Sarcopenia is one of the most common diseases of elderly patients which can affect the physical function and quality of life.Elderly patients not only have high prevalence of type 2 diabetes mellitus,but also have complex polypharmacy.As a result,the risk of antidiabetic agents related skeleton muscle damage and sarcopenia will increase significantly.Therefore,it is extremely important to identify and try to avoid the use of related drugs in the elderly.This article reviewed the types of antidiabetic drugs and mechanism likely leading to sarcopenia,as well as the intervention methods and drug management,to promote the prevention and control of the morbidity of sarcopenia in the elderly and improve the level of rational drug use.

关 键 词：糖尿病 肌肉损伤 肌肉减少症 降糖药 合理用药 

分 类 号：R685[医药卫生—骨科学]